article
Natural products, particularly flavonoids, which possess medicinal properties such as anticancer, anti-inflammatory, and antioxidant effects, are known to inhibit the enzyme xanthine oxidase (XO), which plays a key role in purine metabolism and generates reactive oxygen species (ROS). Inhibiting XO may help manage diseases associated with uric acid accumulation and ROS production. Molecular docking was performed to analyze the interactions of two benzoxanthone-flavonoid compounds, Artonin E and (+)-Artobiloxanthone, with the enzyme XO. These compounds demonstrated excellent stability within the site active of XO, with estimated docking scores of −9.64 and −7.99 kcal/mol, respectively, and formed significant interactions, similar to those observed in the quercetin–XO complex. Additionally, ADMET analyses suggest that these compounds have promising therapeutic potential.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/ecsoc-28-20212
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
